Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
12 Outubro 2022 - 9:00AM
Business Wire
- Poster details the research into CYT-0851
mechanism of action and identification as an inhibitor of
monocarboxylate transporter activity
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company
focused on the discovery and development of next-generation
synthetically lethal therapies for cancer, today announced that the
company will be presenting a poster on the mechanism of action of
CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster
session "Molecular Targeted Agents 1" on Wednesday, October 26,
2022 (Abstract No. 71). Cyteir shared preliminary evidence that
CYT-0851 targeted monocarboxylate transporter (MCT) activity at an
R&D Day in April 2022 and will provide additional mechanistic
data on CYT-0851 at this symposium poster presentation.
“Elucidation of the mechanism of action of CYT-0851 as an
inhibitor of monocarboxylate transporter activity has been an
important accomplishment for the Cyteir Research team,” said Paul
Secrist, PhD, Chief Scientific Officer of Cyteir. “By impairing
monocarboxylate transporter-mediated lactate transport, CYT-0851
disrupts glycolysis, a key metabolic pathway shared broadly by
cancer cells. This knowledge has allowed the team to sharpen its
focus on identifying biomarkers to select the patients most likely
to benefit from CYT-0851 treatment.”
“I am very proud of the Cyteir Research team for the speed with
which they were able to pivot from a phenotypic screen to an
understanding of the molecular target of CYT-0851, complementing
our fast to the clinic development approach,” said Markus
Renschler, MD, President and Chief Executive Officer of Cyteir.
“These research findings may provide additional insights on the
patient population who could benefit from CYT-0851 therapy.”
CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy
and in combination with standard of care chemotherapy and has the
potential to be a first-in-class MCT inhibitor. Translational
analysis of patient samples is ongoing to confirm pharmacodynamic
effects and to identify potential patient selection biomarkers. The
April 2022 R&D Day can be accessed on demand in the Investor
& Media section of the Cyteir website.
About Cyteir Therapeutics, Inc.
Cyteir is a clinical-stage oncology company that is focused on
the discovery and development of next-generation synthetically
lethal therapies to treat cancer. At Cyteir, we employ an
integrated target discovery approach that incorporates a critical
evaluation of the target biology with internal and external
information from a variety of genetic and chemical synthetic
lethality screens to fuel our drug discovery and development
pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a
selective oral investigational drug currently in a Phase 1/2
clinical trial for hematologic malignancies and solid tumors.
Follow Cyteir on social media: LinkedIn and Twitter and at
www.cyteir.com.
Forward-Looking Statements
This press release contains “forward-looking statements” about
Cyteir’s strategy, future plans, and prospects, including
statements regarding the development of Cyteir’s compounds and
potential expansion opportunities, regulatory strategy, and path
for Cyteir’s compounds, and the expected timing and reporting of
results of Cyteir’s preclinical and clinical studies. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,”
“seek,” “will,” “would,” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various factors, risks and
uncertainties, including, but not limited to: that Cyteir’s
clinical trials may fail to demonstrate adequately the safety and
efficacy of any of its drug candidates; that preclinical testing of
Cyteir’s compounds may not be predictive of the results or success
of clinical trials; that the preclinical and clinical development
of Cyteir’s compounds may be delayed or otherwise take longer
and/or cost more than planned; that Cyteir may be unable to
initiate, enroll or complete clinical development of its compounds;
that the continuing global outbreak of COVID-19 (including any
resurgences or variants) may result in development or manufacturing
delays, supply shortages, or shortages of qualified healthcare
personnel; that synthetic lethality, as an emerging class of
precision medicine targets, could result in negative perceptions of
the efficacy, safety or tolerability of this class of targets,
which could adversely affect our ability to conduct our business,
advance our drug candidates or obtain regulatory approvals; and
that Cyteir’s compounds may not receive regulatory approvals or
become commercially successful products. These and other risks and
uncertainties are identified under the heading “Risk Factors” in
Cyteir’s most recent Annual Report on Form 10-K and other filings
Cyteir has made and may make with the Securities and Exchange
Commission ("SEC") in the future, available on the SEC's website at
www.sec.gov.
The forward-looking statements contained in this press release
are based on management's current views, plans, estimates,
assumptions, and projections with respect to future events, and
Cyteir does not undertake and specifically disclaims any obligation
to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221012005227/en/
Lisa Hayes Vice President, Investor Relations and Corporate
Communications 908-868-8926 Lisa.Hayes@cyteir.com
Cyteir Therapeutics (NASDAQ:CYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cyteir Therapeutics (NASDAQ:CYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024